OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
18
Results
Show all
Save search
Copy query
Show results for
Unknown
(18)
Publication Date
Release Date
2021
(6)
2022
(4)
2023
(2)
2020
(2)
2011
(2)
2025
(1)
2013
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
The National Lung Screening Trial: overview and study design.
Not available
S-EPMC3009383
|
biostudies-literature
Cite
Results of the two incidence screenings in the National Lung Screening Trial.
Not available
S-EPMC4307922
|
biostudies-literature
Cite
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Not available
S-EPMC4356534
|
biostudies-literature
Cite
Dexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595
|
biostudies-literature
Cite
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans.
Not available
S-EPMC7272903
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets